<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791581</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00045463</org_study_id>
    <secondary_id>WF 97415</secondary_id>
    <secondary_id>1R01CA199167-01</secondary_id>
    <secondary_id>NCI-2017-00386</secondary_id>
    <secondary_id>NCI-2017-00386</secondary_id>
    <nct_id>NCT02791581</nct_id>
  </id_info>
  <brief_title>Understanding and Predicting Breast Cancer Events After Treatment</brief_title>
  <acronym>UPBEAT</acronym>
  <official_title>Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if patients receiving chemotherapy for breast cancer affects
      the heart, the ability to exercise and fatigue when compared to patients who do not have
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      840 women aged ≥18 years old scheduled to receive chemotherapy for Stage I-III breast cancer
      and a comparison population of 160 women without cancer (1,000 total). Equal numbers of women
      will be recruited aged &lt; 52 vs. &gt; 52. At baseline, innovative MRI measures of CV function (LV
      and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal
      (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and
      psychosocial risk factors; and biomarkers will be collected.

      Measurements will be repeated at 3±1, 12±2 and 24±2 months. This study will assess the
      relevance of pre-existing factors such as age, black/white race, hypertension, smoking
      (yes/no), diabetes, coronary artery disease, menopause status, CV medications, and physical
      activity on the study outcomes. Also, this study will assess dynamic change in modifiable CV
      risk factors (including BMI, blood pressure, serum lipids, serum glucose, physical activity,
      psychosocial factors, lifestyle behaviors), and the cancer treatment including chemotherapy,
      radiation therapy, immunotherapy, and surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2017</start_date>
  <completion_date type="Anticipated">November 17, 2028</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FACT-Fatigue</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants rate the degree to which each item applies in the past 7 days prior to Baseline using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FACT-Fatigue Results</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FACT-Fatigue Results</measure>
    <time_frame>Baseline, 3 months and 12 months</time_frame>
    <description>Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in FACT-Fatigue Results</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MRI Exam Results</measure>
    <time_frame>Baseline, 3 months and 24 months</time_frame>
    <description>The exam will measure left ventricular volumes, ejection fraction, myocardial strain/strain rate, mass, mapping, aortic pulse wave velocity and aortic wall thickness. The exam will take 10 - 15 minutes to complete.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6 Minute Walk Results</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>The purpose of this test is to find out how far the participant can walk in 6 minutes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen's 4-item Perceived Stress Scale (PSS)</measure>
    <time_frame>Baseline, 3 months, 12 months, and 24 months</time_frame>
    <description>A summed scale asking how often over the prior two weeks four aspects of stress were experienced (1=never to 5=very often)
o weeks four aspects of stress were experienced (1=never to 5=very often)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cook-Medley Hostility Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>A 14-item scale used to assess the effect of hostility associated with cardiovascular risk factors.
Minimum Score: 0 Maximum Score: 13 Higher values indicate greater hostility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FACT-Fatigue Results</measure>
    <time_frame>Baseline, 3 months, 12 months, and 24 months</time_frame>
    <description>Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Results</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>The purpose of this test is to find out how far the participant can walk in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAND MOS 36-item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>SF-36 consists of 36 items measuring the following 8 domains: physical function, role limitations due to physical health problems, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional health problems, and mental health. These 8 domains also provide two summary scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Center for Epidemiological Studies Depression Scale (CESD-10)</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Screening questionnaire assessing depressive symptoms during the last week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Godin Leisure-Time Exercise Questionnaire (LTEQ)</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Main process measure of physical activity participation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACE Adult Sedentary Behaviors Survey</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Assess sedentary lifestyle behaviors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Short Form 8A Measure of Sleep Disturbance</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Assess time course and risk factors associated with sleep disturbance and fatigue
Minimum Score: Raw: 8, T-score: 28.9 Maximum Score: Raw: 40, T-score: 76.5 Higher values represent greater sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Applied Cognitive Abilities Short Form 8A and Applied Cognition General Concerns Short Form 8A</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Measurement of different aspects of cognitive functioning.
PROMIS Applied Cognitive Abilities Short Form 8A
- Minimum Score: Raw: 8, T-score: 27.0 Maximum Score: Raw: 40, T-score: 64.8 Higher values represent better cognition.
Applied Cognition General Concerns Short Form 8A
- Minimum Score: Raw: 8, T-score: 23.3 Maximum Score: Raw: 40, T-score: 62.7 Higher values represent better cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Efficacy for Duration Scale</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Comprised of six items and will be included as a measure of exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chair Stands - Measures Leg Strength</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Participants will be first asked to stand from a sitting position without using their arms. If they can perform the task, they will then be asked to stand up and sit down five times as quickly as possible. The time to complete the task will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standing Balance Test</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Participants will be asked to maintain balance for up to 30 seconds in three positions characterized by a progressive narrowing of the base support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Speed Test</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Participants will be instructed to start at a marked walking course with toes touching the start line and when cued to start, will begin walking at their ususal speed. The time to walk from the starting line to the end of the 4-meter walk will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip Strength</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Grip strength is assessed with an isometric handgrip dynamometer while the participant is sitting with the head facing straight ahead. The elbow should be bent at a 90 degree angle and the wrist should be at the mid-prone position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>Baseline, 3 months, 12 months and 24 months</time_frame>
    <description>Range of motion at the shoulder joint will be assessed with shoulder flexion and shoulder abduction with a goniometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KCCQ-12 Questionnaire</measure>
    <time_frame>Baseline, 24 months</time_frame>
    <description>Independently measures the patient's perception of their health status which includes heart failure symptoms (frequency and burden), physical and social limitations, and how their heart failure impacts their QOL within a 2-week recall period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>B-type natriuretic peptide (BNP)</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Serum BNP as a predictor of exercise intolerance</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin - 1</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Acquired to determine associations between troponin levels during therapy and the onset of cardiac and vascular dysfunction, exercise capacity, and fatigue.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.
Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Cancer Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.
Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac MRI</intervention_name>
    <description>Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.
Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.</description>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <arm_group_label>Non-Cancer Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Women with Stage I - III Breast Cancer:

          -  Stage I-III female breast cancer (including inflammatory and newly diagnosed or
             locally recurrent breast cancer) but not metastatic breast cancer being treated with
             curative intent

          -  &gt; 18 years old

          -  Scheduled to receive chemotherapy

          -  Able to hold breath for 10 seconds

          -  ECOG performance status 0 -2

          -  Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or
             fainting

          -  Able to exercise on a treadmill or stationary cycle

          -  Participants in other ongoing clinical trials are eligible for this study

        Exclusion Criteria for Women with Stage I-III Breast Cancer:

          -  Those with ferromagnetic cerebral aneurysm clips or other intracranial metal;
             pacemakers, defibrillators, functioning neurostimulator devices or other implanted
             non-compatible MRI devices

          -  If previously measured, known LVEF &lt;50%

          -  Symptomatic claustrophobia

          -  Unable to provide informed consent

          -  At the beginning of the study, pregnant women and women who are breast-feeding will
             not be enrolled.

          -  Severe pulmonary hypertension

          -  Within the past 6 months:

               -  Acute pulmonary embolus

               -  Deep vein thrombosis

          -  Within the past month:

               -  Heart attack

               -  Unstable or stable angina (cardiac chest pain)

               -  Left main coronary artery disease

               -  Symptomatic heart failure

               -  Uncontrolled hypertension (SBP &gt; 180 mm Hg or DBP &gt; 100mm Hg)

               -  Severe valvular heart disease

               -  Uncontrolled metabolic disease (diabetes with fasting BS &gt;300 mg/dl,
                  thyrotoxicosis, myxedema)

               -  Aortic aneurism (&gt;45 mm diameter) or aortic dissection

               -  Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise

               -  Hypertrophic obstructive cardiomyopathy

          -  Patient does not understand English

        Inclusion Criteria for Women Free of Cancer for Comparison:

          -  Healthy female without known coronary artery disease &gt; 18 years old

          -  Able to hold breath 10 seconds

          -  ECOG performance status = 0 or 1

          -  Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or
             fainting

          -  Able to exercise on a treadmill or stationary cycle

          -  No personal history of cancer other than superficial skin cancers

          -  Has never received chemotherapy, radiation therapy, immunotherapy, or had breast
             cancer related surgery

          -  If previously measured, LVEF ≥ 50%

        Exclusion Criteria for Women Free of Cancer for Comparison:

          -  Inflammatory conditions such as lupus or inflammatory bowel disease

          -  Overt coronary artery disease or heart failure

          -  Those with ferromagnetic cerebral aneurysm clips or other intracranial metal;
             pacemakers, defibrillators, functioning neurostimulator devices or other implanted
             non-compatible MRI devices

          -  Symptomatic claustrophobia

          -  Unable to provide informed consent

          -  At the beginning of the study, pregnant women or women who are breast feeding will not
             be enrolled.

          -  Severe pulmonary hypertension

          -  Within the past 6 months:

               -  Acute pulmonary embolus

               -  Deep vein thrombosis

          -  Within the past month:

               -  Heart attack

               -  Unstable or stable angina (cardiac chest pain)

               -  Left main coronary artery disease

               -  Symptomatic heart failure

               -  Uncontrolled hypertension (SBP &gt; 180 mm Hg or DBP &gt; 100mm Hg)

               -  Severe valvular heart disease

               -  Uncontrolled metabolic disease (diabetes with fasting BS &gt;300 mg/dl,
                  thyrotoxicosis, myxedema)

               -  Aortic aneurism (&gt;45 mm diameter) or aortic dissection

               -  Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise

               -  Hypertrophic obstructive cardiomyopathy

          -  Patient does not understand English
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Hundley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Craver</last_name>
    <phone>(336) 716-0891</phone>
    <email>NCORP@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>317-278-5632</phone>
      <email>iutrials@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Tarah J. Ballinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Springmill Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>317-278-5632</phone>
      <email>iutrials@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Tarah J. Ballinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-865-1125</phone>
    </contact>
    <investigator>
      <last_name>Salim Hayek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital ? Dearborn</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital - Farmington Hills</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Spectrum Health at Butterworth Campus</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>616-391-1230</phone>
      <email>crcwm-regulatory@crcwm.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen J. Yost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Partners Inc</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regions Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology PA-Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>952-993-1517</phone>
      <email>mmcorc@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Pamala A. Pawloski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-832-0836</phone>
      <email>vivian.sheidler@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center at Alamance Regional</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-538-7725</phone>
      <email>kaye.shoffner@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>704-384-5369</phone>
      <email>nnechiporchik@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>William O. Ntim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-832-0821</phone>
      <email>vivian.sheidler@conehealth.com</email>
    </contact>
    <investigator>
      <last_name>Vinay K. Gudena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-474-9892</phone>
    </contact>
    <investigator>
      <last_name>Bonnie Ky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Easley</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Butternut</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Eastside</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Greer</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Seneca</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Institute - Spartanburg</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey K. Giguere</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centra Lynchburg Hematology-Oncology Clinic Inc</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>434-200-5925</phone>
      <email>Kevin.Patel@centrahealth.com</email>
    </contact>
    <investigator>
      <last_name>Mary H. Hackney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Massey Cancer Center at Stony Point</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William G. Hundley</last_name>
      <email>gundley@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>William G. Hundley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>804-628-1939</phone>
      <email>mwellons@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Mary H. Hackney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Southern Lakes VLCC</name>
      <address>
        <city>Burlington</city>
        <state>Wisconsin</state>
        <zip>53105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Health Center-Fond du Lac</name>
      <address>
        <city>Fond Du Lac</city>
        <state>Wisconsin</state>
        <zip>54937</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care Germantown Health Center</name>
      <address>
        <city>Germantown</city>
        <state>Wisconsin</state>
        <zip>53022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Grafton</name>
      <address>
        <city>Grafton</city>
        <state>Wisconsin</state>
        <zip>53024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora BayCare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Kenosha South</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Sinai Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic - Oshkosh</name>
      <address>
        <city>Oshkosh</city>
        <state>Wisconsin</state>
        <zip>54904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Racine</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic-Sheboygan</name>
      <address>
        <city>Sheboygan</city>
        <state>Wisconsin</state>
        <zip>53081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Center in Summit</name>
      <address>
        <city>Summit</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic-Two Rivers</name>
      <address>
        <city>Two Rivers</city>
        <state>Wisconsin</state>
        <zip>54241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee West</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora West Allis Medical Center</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>414-302-2304</phone>
      <email>ncorp@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Thomas J. Saphner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Cardiovascular Events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.</ipd_description>
    <ipd_time_frame>6 months after publication for a 2 year duration</ipd_time_frame>
    <ipd_access_criteria>upon request to NCORP@wakehealth.edu</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

